KR20050073925A - Toothpaste composition - Google Patents
Toothpaste composition Download PDFInfo
- Publication number
- KR20050073925A KR20050073925A KR1020040002049A KR20040002049A KR20050073925A KR 20050073925 A KR20050073925 A KR 20050073925A KR 1020040002049 A KR1020040002049 A KR 1020040002049A KR 20040002049 A KR20040002049 A KR 20040002049A KR 20050073925 A KR20050073925 A KR 20050073925A
- Authority
- KR
- South Korea
- Prior art keywords
- toothpaste
- collagen
- proline
- glutathione
- inflammation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 239000000606 toothpaste Substances 0.000 title description 29
- 229940034610 toothpaste Drugs 0.000 title description 29
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 35
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 32
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 19
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract description 17
- 108010024636 Glutathione Proteins 0.000 claims abstract description 16
- 239000004471 Glycine Substances 0.000 claims abstract description 16
- 229960003180 glutathione Drugs 0.000 claims abstract description 16
- 239000000551 dentifrice Substances 0.000 claims abstract description 11
- 102000008186 Collagen Human genes 0.000 abstract description 19
- 108010035532 Collagen Proteins 0.000 abstract description 19
- 206010061218 Inflammation Diseases 0.000 abstract description 19
- 230000004054 inflammatory process Effects 0.000 abstract description 19
- 229920001436 collagen Polymers 0.000 abstract description 17
- 150000001413 amino acids Chemical class 0.000 abstract description 14
- 230000003078 antioxidant effect Effects 0.000 abstract description 11
- 239000003963 antioxidant agent Substances 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 2
- 210000002200 mouth mucosa Anatomy 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 229960002429 proline Drugs 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 229960002449 glycine Drugs 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 210000002808 connective tissue Anatomy 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000003405 preventing effect Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000000116 mitigating effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 208000002925 dental caries Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000004088 foaming agent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 208000024693 gingival disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 2
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- -1 polyoxy Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 2
- 229960000401 tranexamic acid Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical compound CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000251511 Holothuroidea Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 241000243142 Porifera Species 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000002554 disease preventive effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 241001233061 earthworms Species 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960002089 ferrous chloride Drugs 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- SYUXAJSOZXEFPP-UHFFFAOYSA-N glutin Natural products COc1c(O)cc2OC(=CC(=O)c2c1O)c3ccccc3OC4OC(CO)C(O)C(O)C4O SYUXAJSOZXEFPP-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108060006613 prolamin Proteins 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical group C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000001296 salvia officinalis l. Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K93/00—Floats for angling, with or without signalling devices
- A01K93/02—Floats for angling, with or without signalling devices with signalling devices
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K97/00—Accessories for angling
- A01K97/12—Signalling devices, e.g. tip-up devices
- A01K97/125—Signalling devices, e.g. tip-up devices using electronic components
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Engineering & Computer Science (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 프롤린 또는 글리신 또는 프롤린과 글리신의 혼합물을 글루타치온과 함께 함유함을 특징으로 하는 치약 조성물에 관한 것이다. 본 발명에 따르면The present invention relates to a dentifrice composition characterized in that it contains proline or glycine or a mixture of proline and glycine together with glutathione. According to the invention
, 아미노산을 사용함으로써 구강점막 구성 단백질인 콜라겐의 손상을 막고 염증 등의 원인으로 손상된 콜라겐을 복구하여 증상을 완화시키고 항산화제인 글루타치온에 의해 염증을 억제하여 구강 건강을 지켜주는 기능을 하는 치약조성물이 제공된다.And amino acids are used to prevent collagen, oral mucosa-induced collagen, to repair collagen damaged due to inflammation, to relieve symptoms, and to inhibit inflammation by the antioxidant glutathione to provide oral health. do.
Description
본 발명은 치약 조성물에 관한 것으로, 더욱 구체적으로, 본 발명은 프롤린 또는 글리신 또는 프롤린과 글리신의 혼합물을 글루타치온과 함께 함유함으로써 치은염 치주염 등의 구강염증을 효과적으로 완화, 예방하는 치약 조성물에 관한 것이다.The present invention relates to a dentifrice composition, and more particularly, to a dentifrice composition which effectively alleviates and prevents oral inflammation such as gingivitis periodontitis by containing proline or glycine or a mixture of proline and glycine together with glutathione.
생체의 결합조직을 구성하는 가장 대표적인 단백질은 콜라겐으로 구강 조직도 콜라겐 단백질로 구성되어져 있다. 콜라겐은 섬유성 단백질의 일종으로 1000개 이상의 아미노산이 모여 콜라겐 분자를 만든다. 콜라겐 단백질은 사람의 몸에서는 장기를 감싸는 막, 관절연골, 눈의 각막, 뼈와 피부등에 주로 존재하는데, 특히 뼈를 구성하는 칼슘의 접착제로서의 기능과 주름의 원인이 되는 피부속 진피층의 구성요소로서 매우 중요하다. 결합조직은 몸 전체, 피부, 장기 또는 세포끼리를 결합하거나 지탱시키는 조직으로 간장, 심장 등 전신의 모든 기관이 결합조직으로 존재한다. 특히 진피, 힘줄, 연골, 뼈 등은 결합조직으로만 이루어진 기관이다.The most representative protein constituting the connective tissue of the living body is collagen, oral tissue is also composed of collagen protein. Collagen is a fibrous protein that contains more than 1000 amino acids to form collagen molecules. Collagen protein is mainly present in the human body's membranes, articular cartilage, cornea of the eye, bones and skin.In particular, it is a component of the dermal layer of the skin that causes the function of calcium adhesive and wrinkles. very important. Connective tissue is a tissue that connects or supports the entire body, skin, organs, or cells. All organs such as the liver and heart exist as connective tissue. In particular, the dermis, tendons, cartilage, bones, etc. are organs consisting only of connective tissue.
결합조직의 구성성분은 수분이 가장 많으며 약⅔를 차지한다. 나머지 ⅓은 유기화합물로서 주로 단백질과 다당류이다. 즉, 콜라겐(collagen) 및 엘라스틴(elastin) 단백질과 프로테오글리칸(proteoglycan)이라고 부르는 단백질에 다당(多糖)이 결합한 물질이 주된 구성성분이다. The components of the connective tissue are the most watery and occupy the drug. The other two are organic compounds, mainly proteins and polysaccharides. That is, the main component is a substance in which polysaccharide is bound to a collagen, elastin protein, and a protein called proteoglycan.
콜라겐은 단백질의 일종으로 세포 속의 많은 단백질이나 혈액 속의 단백질처럼 물에 녹은 상태로써는 거의 존재하지 않고 섬유의 상태로 존재한다. 콜라겐의 섬유는 몸이나 장기를 지탱하거나, 결합하거나, 보강하거나, 또는 경계면을 만드는 등 결합조직의 가장 기본적인 역할을 지니고 있으며 몸 속에 가장 많이 있는 단백질이다. Collagen is a kind of protein. Like many proteins in cells or proteins in blood, collagen is hardly present in the water, but in the form of fibers. Collagen fiber has the most basic role of connective tissue, supporting the body or organs, binding, reinforcing, or creating an interface, and is the most protein in the body.
콜라겐은 포유동물을 비롯하여 조류, 파충류, 어류에서부터 해삼, 지렁이, 해면 등에 이르기까지 동물계에서 널리 볼 수 있다. 콜라겐은 생체내 다른 단백질과는 달리 그 구성 아미노산 중 글리신과 프롤린 등 소수성 아미노산의 함량이 매우 높은 특성을 가지고 있다.Collagen is widely found in the animal world, from mammals to birds, reptiles and fish to sea cucumbers, earthworms and sponges. Collagen, unlike other proteins in vivo, has a very high content of hydrophobic amino acids such as glycine and proline among its constituent amino acids.
프롤린은 C5H9NO2 의 화학식으로, 피롤리딘-2-카르복실산의 구조를 가진다. 1901년 E.피셔가 카제인의 가수분해 도중에 처음 분리하여 프롤린이라고 명명했으며, DL-프롤린은 1899년 R.빌슈테터가 합성에 성공하였다. L-프롤린은 프롤라민, 프로타민, 카제인, 젤라틴 등 여러 단백질에 함유되어 있는데, 특히 콜라겐 및 그 변성물인 젤라틴에 많다. 감미가 있는 무색 결정으로, 에탄올에 녹는 유일한 아미노산이며 물에 대한 용해도는 단백질을 이루는 아미노산 중에서 가장 높다.Proline is a chemical formula of C 5 H 9 NO 2 , having a structure of pyrrolidine-2-carboxylic acid. In 1901 E. Fischer first isolated during casein hydrolysis and named proline, and DL-proline was synthesized by R. Wilstedter in 1899. L-proline is contained in several proteins such as prolamin, protamine, casein, gelatin, and especially in collagen and its modified gelatin. Sweet, colorless crystals, the only amino acid that is soluble in ethanol and has the highest solubility in water.
글리신은 글리코콜(glycocoll) 또는 아미노아세트산이라고도 하며 화학식은 NH2CH2COOH으로 나타내어진다. 단백질의 가수분해물에서 최초로 추출된 비(非)필수아미노산이다. 무색의 주상결정으로, 232~236℃에서 거품을 내며 분해된다. 물에는 녹으나, 알코올 ·에테르 등의 유기용매에는 거의 녹지 않는다. 아미노산 중에서 비대칭 탄소원자를 가지지 않는 유일한 것으로, 광학이성질체는 없다. 1820년 H.브라코노(1780~1855)가 처음으로 콜라겐에서 추출했으며, 감미가 있어 글리코콜이라고 하였다. 일반적으로 식물성 단백질에는 거의 함유되어 있지 않으나, 동물성 단백질에는 다량으로 함유되어 있다. 예를 들면, 견사(絹絲) 피브로인에는 40.7%, 젤라틴에는 25.5%가 함유되어 있다. 또, 옥시토신이나 바소프레신 등의 호르몬, 글루타티온 등 단백질의 각 구성성분이기도 하다. 동물체 내에서는 세린과의 상호전환 반응에 의해 합성되며, 글리옥실산에 글루탐산 또는 글루타민이 아미노기 공급원이 되어 글루신을 생성한다. 또, 생체내 대사에도 중요한 역할을 하는데, 핵산의 염기성분인 퓨린, 에너지 대사에 관여하는 크레아틴을 비롯하여 혈색소, 엽록소, 비타민 B의 포르피린 합성 등에도 관여한다.Glycine is also called glycocoll or aminoacetic acid and the formula is represented by NH 2 CH 2 COOH. It is a non-essential amino acid first extracted from the hydrolyzate of a protein. It is a colorless columnar crystal, decomposed with foaming at 232 ~ 236 ℃. It is soluble in water but hardly soluble in organic solvents such as alcohol and ether. The only amino acid with no asymmetric carbon atom, no optical isomers. In 1820, H. Bracono (1780-1855) first extracted from collagen. Generally, vegetable protein is rarely contained, but animal protein is contained in large amounts. For example, silk yarn fibroin contains 40.7% and gelatin 25.5%. Moreover, it is also a component of proteins, such as hormones, such as oxytocin and vasopressin, and glutathione. In animals, it is synthesized by an interconversion reaction with serine, and glutamic acid or glutamine becomes a source of amino groups in glyoxylic acid to produce glutin. In addition, it plays an important role in metabolism in vivo, and is involved in the synthesis of hemoglobin, chlorophyll, and vitamin B porphyrin as well as purine, which is a base component of nucleic acid, and creatine involved in energy metabolism.
글루타치온(Glutathione)은 세 개의 아미노산으로 이루어진 일종의 펩타이드Glutathione is a peptide consisting of three amino acids
(peptide)로써 그 구성 아미노산은 글루타민산, 시스테인, 글리신 등이다. 글루타치온은 간에서 만들어지며 매우 강력한 항산화 물질로 체내 라디칼 또는 활성산소의 제거력을 가지고 있다. 또한 체내에서 시스테인과 함께 글루타치온 과산화효소의 역가를 증가시킨다. 이 효소는 활성산소(프리레디칼)가 생체 여러 부분을 손상시키지 못하도록 해준다. 글루타치온 과산화효소는 DNA의 복구, T임파구의 활성화, 기타 각종 함암효과를 지니고 있다. 또한, 활성산소의 형성을 방지해 주고, 활성산소에 의해 이미 손상된 세포조직을 보호해 주기도 한다. As the peptide, its constituent amino acids are glutamic acid, cysteine, glycine and the like. Glutathione is made in the liver and is a very powerful antioxidant that removes radicals or free radicals from the body. It also increases the titer of glutathione peroxidase along with cysteine in the body. This enzyme prevents free radicals from damaging parts of the body. Glutathione peroxidase has DNA repair, T lymphocyte activation, and various other cancer-causing effects. It also prevents the formation of free radicals and protects cellular tissues already damaged by free radicals.
지금까지의 치약을 비롯한 구강제품에 비단백태 아미노산의 일종인 트라넥사민산(Tranexamic Acid) 등이 잇몸질환의 예방 및 완화 소재로 사용된 예가 있지만 글리신, 프롤린 등의 생체 아미노산과 글루타치온 등의 펩타이드가 적용된 예는 없었다. In the past, toothpaste and other oral products such as tranexamic acid, a kind of non-protein amino acid, have been used for the prevention and alleviation of gum disease, but biological amino acids such as glycine and proline and peptides such as glutathione No example was applied.
기존의 치약제에 잇몸염증 예방 또는 완화소재로는 아미노카프론산, 비타민E아세테이트(초산토코페롤), 알란토인 및 그 유도체, 트라넥사민산, 소금, 염산피리독신(비타민B6) 등이 사용되었다. 하지만 이들 소재로서 그 효과를 충분히 달성하기 어려웠고 일부 소재의 경우 치약 상태 안정성의 변화를 야기시켜 효능효과를 나타내기에 충분한 양을 적용하기 어려운 점이 있었다.As a material for preventing or alleviating gum inflammation in the existing toothpaste, aminocaproic acid, vitamin E acetate (tocopherol acetate), allantoin and its derivatives, tranexamic acid, salt, pyridoxine hydrochloride (vitamin B6), and the like have been used. However, these materials were difficult to achieve the effect sufficiently, and some materials were difficult to apply a sufficient amount to cause the efficacy effect by causing a change in toothpaste stability.
본 발명은 치주염, 치은염 등 잇몸질환의 예방 및 치료를 위하여 프롤린 또는 글리신 또는 프롤린과 글리신의 혼합물을 글루타치온과 함께 적용한 치약조성물이 기존의 동일목적의 치약제에 비해 훨씬 향상된 효능, 효과를 나타낸다는 놀라운 사실을 밝혀내고 본 발명을 완성하기에 이르렀다. The present invention is surprising that the dentifrice composition with proline or glycine or a mixture of proline and glycine together with glutathione for the prevention and treatment of gum disease such as periodontitis and gingivitis exhibits much improved efficacy and effect than conventional toothpaste. The facts have been discovered and the present invention has been completed.
본 발명은 프롤린 또는 글리신 또는 프롤린과 글리신의 혼합물을 글루타치온과 함께 함유함을 특징으로 하는 치약 조성물에 관한 것이다. The present invention relates to a dentifrice composition characterized in that it contains proline or glycine or a mixture of proline and glycine together with glutathione.
본 발명의 치약 조성물은 최종 상품의 제형 및 포장 형태로서 기존의 연고상The toothpaste composition of the present invention is a conventional ointment as a formulation and packaging form of the final product.
(페이스트상)의 튜브에 적용될 수 있다. 본 발명의 치약 조성물에서 아미노산류 중 글리신과 프롤린은 각각 치약 조성물 중 무게로서 치약 100그람 중 각각 0.001 내지 1.0그람의 양으로서 사용되며, 글루타치온은 0.001 내지 0.5 그람의 양으로서 사용되며 이들 농도 범위 이하에서는 그 효과가 미약하고 그 이상에서는 효과 상승 요인에 비하여 코스트가 상승되며 조성물의 향취 및 안정성이 좋지 못하다.It can be applied to a tube (on paste). In the dentifrice composition of the present invention, glycine and proline in amino acids are each used as an amount of 0.001 to 1.0 grams in 100 grams of toothpaste as a weight in the dentifrice composition, and glutathione is used in an amount of 0.001 to 0.5 grams and below these concentration ranges. The effect is weak and above that, the cost is increased compared to the effect increase factor, and the fragrance and stability of the composition are not good.
본 발명에 의한 치약 조성물은 아미노산 및 펩타이드류에 의하여 잇몸 염증을 완화시켜준다는 사실을 임상적 실험을 통해 증명될 수 있으며 이는 본 발명에 의한 치약 조성물이 아미노산 및 펩타이드류에 의한 항산화효과로 잇몸염증의 원인이 되는 활성산소의 발생을 억제하여 잇몸염증을 예방하고 잇몸조직의 구성 단백질인 콜라겐의 생합성을 도와 염증을 완화할 수 있음을 의미한다.The toothpaste composition according to the present invention can be proved through clinical experiments to reduce gum inflammation by amino acids and peptides, which is the antioxidant effect of the toothpaste composition according to the present invention amino acids and peptides It means that it is possible to prevent gum inflammation by inhibiting the generation of causative free radicals and to help relieve inflammation by aiding the biosynthesis of collagen, a constituent protein of gum tissue.
본 발명의 치약조성물에서 사용된 연마제들의 종류와 사용량은 침강 실리카, 실리카 겔, 지르코늄 실리케이트, 인산일수소칼슘, 무수인산일수소칼슘, 함수알루미나, 경질탄산칼슘, 중질탄산칼슘, 칼슘피로인산염, 불용성메타인산염 및 알루미늄 실리케이트 중에서 선택된 1종 이상을 5 내지 60 중량% 사용하며, 입자 크기도 연마제의 종류에 따라 다르지만 평균 입자경이 20마이크로 이하인 것을 사용하는 것이 바람직하다.The type and the amount of abrasive used in the toothpaste composition of the present invention is precipitated silica, silica gel, zirconium silicate, calcium dihydrogen phosphate, anhydrous calcium monohydrogen phosphate, hydrous alumina, hard calcium carbonate, heavy calcium carbonate, calcium pyrophosphate, insoluble 5 to 60% by weight of at least one selected from metaphosphate and aluminum silicate is used, and although the particle size also varies depending on the type of abrasive, it is preferable to use an average particle diameter of 20 micro or less.
치약 중 습윤제의 사용은 연고상의 제형을 만드는데 필수적인 성분으로 치약이 공기 중에 노출될 때 건조 고화되는 것을 방지하고 치약의 표면에 윤기를 제공할 뿐만 아니라 종류에 따라 양치시 감미를 주는 역할을 한다. 본 발명에서는 농글리세린(98%), 글리세린(85%), 소르비톨 수용액(70%), 비결정성 소르비톨 수용액(70The use of humectants in toothpaste is an essential ingredient in the preparation of ointment formulations, which prevents the toothpaste from drying and solidifying when exposed to the air and gives the surface of the toothpaste a glow, as well as sweetening the toothpaste. In the present invention, concentrated glycerin (98%), glycerin (85%), sorbitol aqueous solution (70%), amorphous sorbitol aqueous solution (70
%), 자이리톨, 폴리에틸렌글리콜류 및 프로필렌글리콜 중에서 선택된 1종 이상을 20내지 70중량% 사용한다.%), 20 to 70% by weight of one or more selected from ziitol, polyethylene glycols and propylene glycol.
또한 통상적인 치약 조성물에서도 사용 목적에 따라 적당한 약효 성분을 사용할 수 있는데, 치아에 불소막을 형성하여 충치균의 대사산물인 산(젖산 등)에 강하게 만드는 불화물의 사용은 치약 조성물에서 필수 성분이라 할 수 있다. 또한 치주 질환을 예방하기 위한 방법으로서 아미노카프론산, 알란토인 및 알란토인 유도체, 비타민류가 동시에 사용될 수 있으며 구강내 유해 미생물의 번식을 억제하여 구강위생을 증진시킬 목적으로 트리클로산 등이 동시에 사용될 수 있다. In addition, a conventional dentifrice composition may use a suitable medicinal ingredient depending on the purpose of use. The use of a fluoride which forms a fluorine film on the teeth and makes it resistant to acid (lactic acid, etc.), which is a metabolite of caries, can be an essential ingredient in toothpaste compositions. . In addition, as a method for preventing periodontal disease, aminocapronic acid, allantoin and allantoin derivatives and vitamins may be used at the same time, and triclosan may be used simultaneously for the purpose of improving oral hygiene by inhibiting the reproduction of harmful microorganisms in the oral cavity.
치약 중의 결합제의 사용은 고체인 분말 성분과 액체 성분이 분리되지 않게 해주는 역할로 연고상의 치약에서는 필수적인 것이며 수용성 고분자 종류라면 어떤 것이든 사용될 수 있다. 일반적으로 많이 사용되는 성분으로는 셀룰로오스로부터 유래된 카르복시메틸셀룰로오스나트륨, 해조류로부터 추출된 카라기난류 및 미생물의 대사로부터 얻어지는 산탄검 등을 들 수 있다.The use of binders in toothpaste is essential to ointment toothpaste as it prevents the separation of solid powder and liquid components and can be used as long as it is a water-soluble polymer. Commonly used components include sodium carboxymethyl cellulose derived from cellulose, carrageenan extracted from seaweed, and xanthan gum obtained from metabolism of microorganisms.
방부제는 미생물에 대한 오염을 방지하여 치약의 보존을 장기화하는 데 도움을 줄 수 있으며 대표적인 것으로 벤조산 류, 파라벤 류 등이 있다.Preservatives can help to prolong toothpaste preservation by preventing microbial contamination. Representatives include benzoic acid and parabens.
또한, 기포제의 사용은 제품의 사용감을 증진시키고 세정작용을 도와주며 기타 약효성분의 분산 및 침투를 신속하게 하고 계면 장력을 감소시킴으로써 구강내 이물질을 쉽게 떨어지게 하는 작용을 한다. 기포제로는 주로 음이온성 계면활성제인 라우릴 황산나트륨이 사용되며 제형의 특성에 따라 보조적으로 비이온성 계면활성제인 폴리옥시에틸렌폴리옥시프로필렌의 공중합체(폴록사머), 폴리옥시에틸렌경화피마자유, 폴리옥시에틸렌소르비탄 지방산에스테르 등이 사용된다.In addition, the use of foaming agent to enhance the feeling of use of the product, to help the cleaning action, and to act to easily remove foreign substances in the oral cavity by speeding up the dispersion and penetration of other active ingredients and reducing the interfacial tension. As the foaming agent, sodium lauryl sulfate, which is an anionic surfactant, is mainly used, and a copolymer of polyoxyethylene polyoxypropylene (poloxamer), polyoxyethylene-cured castor oil, and polyoxy, which is auxiliary nonionic surfactant depending on the characteristics of the formulation. Ethylene sorbitan fatty acid ester and the like are used.
그밖에 본 발명에 따른 치약 조성물의 사용감을 좋게 하기 위해 향료, 감미제 및 색소류 등을 사용할 수 있으며 이러한 목적을 위해서는 식용 향료의 사용이 필수적이며, 페파민트 오일, 스피아민트 오일, 세이지, 유칼립톨, 메틸살리실레이트 및 과일 추출물 등을 사용할 수 있다. 감미제로는 삭카린 나트륨이 가장 많이 사용되고 있으며 색소로는 주로 식용 색소를 사용한다. In addition, in order to improve the feeling of use of the toothpaste composition according to the present invention can be used flavors, sweeteners and pigments, and for this purpose, the use of edible spices is essential, peppermint oil, spearmint oil, sage, eucalyptol, methylsalley Silates, fruit extracts, and the like. The most commonly used sweetener is sodium saccharin, and food coloring is mainly used.
이상의 성분들로 구성된 본 발명의 조성물과 기존의 시판되고 있는 잇몸질환 예방치약 및 일반 충치 예방 및 프라그 제거용 치약류를 여러 측면에서 효과 및 안정성을 비교 시험 평가 해본 결과 본 발명에 의한 치약 조성물이 우수한 것으로 나타났으며 (표2,3,4및 5참조), 따라서 본 발명자들이 의도했던 효과를 달성하였음을 확인 하였다. The composition and composition of the present invention and the existing commercially available gum disease preventive toothpaste and tooth decay for preventing tooth decay and plaque in various aspects have been tested and evaluated in terms of effectiveness and stability. (See Tables 2, 3, 4 and 5), thus confirming that the inventors achieved the intended effect.
이하 본 발명을 하기 실시예 및 비교예에 의거하여 더욱 구체적으로 설명한다. 그러나 이는 본 발명의 이해를 돕기 위한 것일 뿐, 어떤 의미로든 본 발명의 기술적 범위가 이에 한정 되지는 않는다.Hereinafter, the present invention will be described in more detail based on the following Examples and Comparative Examples. However, this is only to help the understanding of the present invention, the technical scope of the present invention in any sense is not limited thereto.
실시예 1 내지 5 및 비교예 1 내지 3Examples 1-5 and Comparative Examples 1-3
하기 표1에 나타낸 바와 같은 구성비로 본 발명에 따른 치약조성물 ( 실시예 1 내지 5 ) 및 이와 비교 하기 위한 기존의 치약 조성물 ( 비교예 1 내지 3 )을 제조 하였다. 제조방법을 설명하면 다음과 같다. 습윤제에 결합제 및 기타 첨가제등을 미리 분산하고 연마제 및 아미노산류 등 약효성 성분을 투입 한 후 약30 분간 교반 하였다. 마지막으로 기포제와 향료 성분을 투입한 후 진공 상태에서 20분간 교반 시켜 최종 제품 을 수득 하였다. Toothpaste composition according to the present invention (Examples 1 to 5) and the existing toothpaste composition (Comparative Examples 1 to 3) for comparison with the composition ratio as shown in Table 1 was prepared. The manufacturing method is as follows. The binder and other additives were previously dispersed in the humectant, and the active ingredients such as the abrasives and amino acids were added, followed by stirring for about 30 minutes. Finally, the foaming agent and the fragrance component were added, followed by stirring for 20 minutes in a vacuum state to obtain a final product.
표 1Table 1
실험예1. 임상적 구강염증 완화효과 평가Experimental Example 1. Clinical oral inflammation mitigation effect evaluation
상기 실시예 및 비교예 조성물의 구강염증 완화효과를 임상적으로 확인하기 위하여 구강염증을 앓고 있는 20세에서 40세의 남 여 400명을 선출 하여 8개 그룹으로 나눈 후 실험 대상자들에 대하여 Loe와 Silness의 치은지수 평점기준에 따라 상하악 전치부순측의 변연치은과 유두치은을 대상으로 일차 구강 검사를 한 후, 검사결과가 차이가 없도록 각각의 실시예와 비교예 사용군으로 나누었다. 같은 칫솔을 제공하고 습관화된 방법으로 양치를 하게 하여 6개월 경과 단계에서 일차 구강검사와 같은 방법으로 구강검사를 하였다. 측정된 결과로 t-검증을 하여 비교예들과의 차이를 비교하였다. 그 결과는 다음 표 2와 같다.In order to clinically confirm the oral inflammation mitigation effect of the compositions of Examples and Comparative Examples, 400 male and female 20 to 40 year olds with oral inflammation were selected and divided into eight groups. After the primary oral examination of the marginal gingival and papillary gingival of the upper and lower anterior labial cavities according to the gingival index score of Silness, the test results were divided into the use groups of the Examples and Comparative Examples. The same toothbrush was provided and brushed in a customary manner, and the oral examination was performed in the same manner as the primary oral examination at the stage of 6 months. The measured results were t-tested to compare the differences with the comparative examples. The results are shown in Table 2 below.
표 2TABLE 2
유의성 * : 실험시작단계와 6개월 경과 단계의 치은 지수 t-검증Significance *: gingival index t-test at the beginning of the experiment and at 6 months
유의성 1 : 비교예 1과의 t-검증, Significance 1: t-test with Comparative Example 1,
유의성 2 : 비교예 2와의 t-검증, Significance 2: t-test with Comparative Example 2,
유의성 3 : 비교예 3과의 t-검증Significance 3: t-test with Comparative Example 3
상기 표 2의 결과에서 보는 바와 같이 실시예의 조성물들을 사용한 그룹의 치은지수가 통계적으로 유의미하게 감소하였으며, 비교예와도 통계적으로 유의미한 차이를 볼 수 있었다. 이상의 결과에서 본 발명의 조성물은 기존의 구강염증 완화성분에 비해 구강염증 완화효과가 우수한 것으로 분석 평가되었다As shown in the results of Table 2, the gingival index of the group using the compositions of the examples was statistically significantly reduced, and also statistically significant differences with the comparative example. In the above results, the composition of the present invention was analyzed and evaluated to be superior to the oral inflammation mitigation effect compared to the conventional oral inflammation mitigation component.
실험예 2. 실험실적 활성 산소 발생억제효과Experimental Example 2 Inhibitory Effect of Laboratory Active Oxygen Generation
잇몸 염증 예방 효과를 비교하기 위하여 염증 유발 물질로 알려진 활성 산소의 발생 억제효과를 시험을 통하여 비교 평가 하였다. 글루타치온이 포함된 실시예 및 비교예의 조성물 1.0g을 대식세포(Macrophage)에 처리 후 자극원으로 포볼미리스테이트아세테이트를 처리하여 활성 산소를 발생시킨다. 이 때 발생되는 활성산소에 루미놀 처리로 화학발광을 야기하여 그 값을 측정하여 비교예3과 비교하여 염증 억제율을 구한다. 그 결과는 표 3와 같다. In order to compare the effect of preventing gum inflammation, the inhibitory effect of free radical generation, known as an inflammation-inducing substance, was compared and evaluated through a test. 1.0 g of the compositions of Examples and Comparative Examples containing glutathione were treated to macrophages and treated with pobolmystate acetate as a stimulus to generate active oxygen. In this case, chemiluminescence is caused by luminol treatment on the active oxygen generated, and the value thereof is measured, and the inhibition rate of inflammation is obtained by comparison with Comparative Example 3. The results are shown in Table 3.
억제율(%) = 비교예1의 화학 발광량-실시예의 화학 발광량 ×100% Inhibition = chemiluminescence of Comparative Example 1-chemiluminescence of Example x100
비교예3의 화학 발광량 Chemiluminescence of Comparative Example 3
표 3TABLE 3
상기 표3에서와 같이, 실시예 중 글루타치온을 함유하는 조성물 들이 비교예에 비교하여 월등히 높은 활성산소 발생억제 효과를 보여 항 염증효과가 우수한 것으로 나타났다.As shown in Table 3, the composition containing glutathione in the examples showed a significantly higher active oxygen generation inhibitory effect compared to the comparative example was excellent in the anti-inflammatory effect.
실험예 3. 실험실적 치약제의 항산화 효과 평가Experimental Example 3. Evaluation of Antioxidant Effect of Laboratory Toothpaste
잇몸 염증 예방 효과를 비교하기 위하여 치약제의 항산화 효과를 시험을 통하여 비교 평가 하였다. 항산화 효과를 비교 평가하기 위하여 글루타치온이 포함된 실시예 및 비교예의 조성물 1.0g을 3mL의 10mM리놀레익산(Linoleic acid)용액(1mM 인산완충용액 pH 7.0)에 처리 후 37℃ 항온기에 18시간 유지 시킨 후 0.1mL를 취하여9.1mL의 70% 에칠알콜(Ethanol)과 0.1mL의 30% 암모늄치오씨아네이트(ammonium thiocyanate), 0.1mL의 20mM염화철(Ferrous Chloride)을 가하고 3분간 유지한다. 시액을 원심 분리 후 분광광도계(Spectrop hotometer)를 이용하여 500nm에서 흡광도를 측정하여 그 측정 값을 비교예3의 흡광도와 비교하여 항산화율을 구한다. 그 결과는 표 4와 같다. In order to compare the effects of gum inflammation, the antioxidant effect of toothpaste was evaluated. In order to evaluate the anti-oxidant effect, 1.0 g of the composition of Example and Comparative Example containing glutathione was treated with 3 mL of 10 mM linoleic acid solution (1 mM phosphate buffer solution pH 7.0) and then maintained at 37 ° C. for 18 hours. Then, 0.1 mL of the solution was added, followed by adding 9.1 mL of 70% Ethanol, 0.1 mL of 30% ammonium thiocyanate, and 0.1 mL of 20 mM Ferrous Chloride and maintained for 3 minutes. After centrifugation of the test solution, the absorbance was measured at 500 nm using a spectrophotometer, and the measured value was compared with the absorbance of Comparative Example 3 to obtain an antioxidant rate. The results are shown in Table 4.
항산화율(%) = 비교예3의 흡광도-실시예의 흡광도 ×100% Antioxidant = absorbance of Comparative Example 3-absorbance of Example × 100
비교예3의 흡광도 Absorbance of Comparative Example 3
표 4Table 4
상기 표4에서와 같이 실시예의 조성물이 비교예에 비교하여 월등히 높은 항산화 효과를 보여 염증 억제효과가 우수한 것으로 나타났다.As shown in Table 4, the composition of the Example showed an excellent anti-oxidant effect compared to the comparative example was excellent in the inflammation inhibitory effect.
실험예 4. 치약조성물의 안정성 비교평가Experimental Example 4. Comparative evaluation of the stability of the toothpaste composition
실시예 및 비교예의 치약 조성물을 상온 및 40℃에서 보관 하면서 다음의 기준에 따라 일정 기간 간격으로 치약 조성물의 상태 안정성을 평가 하였다. The state stability of the toothpaste composition was evaluated at regular intervals according to the following criteria while the toothpaste compositions of Examples and Comparative Examples were stored at room temperature and 40 ° C.
<< 평가 기준 >><< evaluation criteria >>
◎ 매우 양호 : 표면이 매끈하고 상 분리가 없으며 정상적인 치약 ◎ Very good: smooth surface, no phase separation, normal toothpaste
O 비교적 양호 : 표면만 약간 거칠거나 튜브 입구 부분만 약간 불량함 Relatively good: only the surface is slightly rough or the tube entrance is slightly bad
∇ 비교적 불량 : 상 분리 현상이 보이고 변색 현상도 조금 나타남불량 relatively poor: phase separation and slight discoloration
×매우 불량 : 상 분리가 심하고 가스 발생 혹은 경화 현상등 나타남 × Very poor: severe phase separation and gas generation or hardening
표 5Table 5
실시예의 조성물들이 비교예의 조성물들에 비해 상태 안정성에 있어서도 모두 양호한 것으로 평가 되었다.The compositions of the examples were all evaluated as good in terms of state stability as compared to the compositions of the comparative examples.
본 발명에 따른 치약조성물은 아미노산을 사용함으로써 구강점막 구성 단백질인 콜라겐의 손상을 막고 염증 등의 원인으로 손상된 콜라겐을 복구하여 증상을 효과적으로 완화시키고 항산화제인 글루타치온에 의해 염증을 억제하여 구강 건강을 지켜주는 기능을 한다. The toothpaste composition according to the present invention prevents damage of collagen, which is an oral mucosa component protein, and repairs collagen damaged by inflammation, etc., effectively alleviating symptoms and inhibiting inflammation by the antioxidant glutathione, thereby protecting oral health. Function
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040002049A KR20050073925A (en) | 2004-01-12 | 2004-01-12 | Toothpaste composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040002049A KR20050073925A (en) | 2004-01-12 | 2004-01-12 | Toothpaste composition |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20050073925A true KR20050073925A (en) | 2005-07-18 |
Family
ID=37262805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040002049A KR20050073925A (en) | 2004-01-12 | 2004-01-12 | Toothpaste composition |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20050073925A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101272225B1 (en) * | 2011-01-20 | 2013-06-11 | 이선정 | Jelly toothpaste and process for preparing the same |
US9125826B2 (en) | 2011-12-21 | 2015-09-08 | Colgate-Palmolive Company | Oral care compositions |
-
2004
- 2004-01-12 KR KR1020040002049A patent/KR20050073925A/en not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101272225B1 (en) * | 2011-01-20 | 2013-06-11 | 이선정 | Jelly toothpaste and process for preparing the same |
US9125826B2 (en) | 2011-12-21 | 2015-09-08 | Colgate-Palmolive Company | Oral care compositions |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2355420C2 (en) | Toothpaste containing lactulose, betaine, chondroitin sulphate and enzymes: papain, lysocim, ribonuclease and lidase | |
US20070098650A1 (en) | Dental formulation | |
FR2587209A1 (en) | COMPOSITIONS FOR COMBATTING HARD BRAIN CONTAINING ZINC SALT AND A KETONIC DERIVATIVE AND METHOD OF USE | |
RU2381021C2 (en) | Liposome containing tooth paste | |
RU2293551C1 (en) | Composition for mouth cavity disease prophylaxis | |
JP7463429B2 (en) | Oral Composition | |
US4853213A (en) | Use of periwinkle in oral hygiene | |
US6056944A (en) | Pharmaceutical compositions for oral use including an NSAID and ceramides | |
JP2020109071A (en) | Agent for inhibiting activity of periodontal pathogen-producing cysteine protease | |
AU2016381178B2 (en) | Mucin coated silica for bacterial aggregation | |
CN116650493A (en) | Use of escitalopram or derivatives thereof for preventing and/or ameliorating gum damage caused by cigarette smoke and method for achieving the use | |
JP2001151690A (en) | Composition for oral cavity | |
FR2882256A1 (en) | COSMETIC USE OF AT LEAST ONE AC-N-SER-ASP-LYS-PRO NATURAL TETRAPEPTIDE OR ONE OF ITS ANALOGUES AS AN AGENT TO SLOW DOWN THE FALL OF HAIR AND / OR STIMULATE THEIR GROWTH | |
FR2590169A1 (en) | Cosmetic composition containing biostimulins | |
KR20050073925A (en) | Toothpaste composition | |
RU2527691C1 (en) | Tooth paste containing buffer mixture | |
KR20150010550A (en) | Compositions for oral-care | |
JP2003176225A (en) | Composition for oral cavity and external use for skin | |
JP4546139B2 (en) | Oral composition | |
KR0170108B1 (en) | Toothpaste composition containing guaiac and coloring compositions | |
BR112021012124A2 (en) | METHODS FOR INHIBITING THE RECRUITMENT OF NEUTROPHILS TO THE GINGIVAL CREVISION | |
RU2527692C1 (en) | Tooth paste containing complex of hydrolases | |
RU2496469C2 (en) | Nonabrasive tooth paste containing enzyme papain, sphagnum extract, polymethylvinyl alcohol - maleic acid copolymer sodium-calcium salt, n-cocoyl ethyl arginate d,l-pyrrolidone carboxylate and sodium fluoride | |
BR112019021767A2 (en) | oral care products and methods | |
RU2535051C1 (en) | Tooth paste |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |